International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationDose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial)
Introduction
Prostate cancer has become the most frequent malignancy in men in Western countries. Beside definitive radiotherapy (RT), prostatectomy, and hormonal therapy (HT), observation might be applied in early-stage low-risk disease. Our group and others 1, 2, 3 have demonstrated that escalating the dose of RT not only improves tumor control but also increases late toxicity. The Dutch randomized trial (CKTO 96-10) has shown that freedom from failure at 7 years was significantly better in the 78-Gy arm compared with the 68-Gy arm (54% vs. 47%; p = 0.04). Although there was no difference in overall survival, late gastrointestinal (GI) toxicity was increased in the 78-Gy arm (p = 0.04) (3). Beside the achievement of cure as the primary goal of radical treatment of prostate cancer, toxicity and assessment of quality of life (QoL) have become very important secondary considerations, especially in view of the arguments in favor of watchful waiting.
To date, none of the randomized dose-escalation studies have thoroughly reported on the impact of dose escalation of RT on QoL by using validated QoL questionnaires.
The present analysis was undertaken within the framework of the Dutch randomized trial (CKTO 96-10) to assess the impact of dose escalation on QoL of prostate cancer patients treated with either 68 or 78 Gy using three-dimensional conformal RT techniques (3D-CRT). The analysis was done by intention to treat. We used a validated QoL questionnaire (SF-36) (4) to investigate the impact of increasing the dose of RT on QoL and the changes over time in different scales of SF-36 in these patients. Correlation of different independent covariates with QoL was also investigated.
Section snippets
Patients and Methods
Between June 1997 and February 2003, 669 patients with localized prostate cancer were enrolled in the Dutch trial (CKTO 96-10) and randomly assigned to receive either 68 or 78 Gy of 3D-CRT. The trial was carried out at four Dutch cancer institutions (3). Briefly, patients with localized prostate cancer with initial prostate-specific antigen (PSA) level ≤60 μg/L were eligible. Patients with low-risk disease, with lymphatic or distant metastases, and those having Karnofsky scores ≤70 were
Baseline patient characteristics
Of the 404 patients treated at the Erasmus MC–Daniel den Hoed Cancer Center, 300 patients (responders, 74%) have participated in the QoL part of the study, filling out at least one QoL questionnaire. There were no differences between responders and nonresponders with respect to age, tumor stage, PSA, adjuvant HT, or presence of comorbidity. More patients among responders had higher Gleason scores as compared with nonresponders (p = 0.005). Among the responders, patient characteristics were
Discussion
Several factors make the assessment of the impact of any treatment modality on QoL extremely important in patients with localized prostate cancer. First, most patients are asymptomatic, owing to the early diagnosis because of elevated PSA level. Second, there are several treatment modalities available, and watchful waiting is an alternative option for early-stage prostate cancer, especially in elderly men with a short expected life span. Third, patients may survive for a considerable period
Conclusion
Quality of life scores in prostate cancer patients as measured by the SF-36 questionnaire did not seem to be significantly decreased by escalating the dose of RT from 68 to 78 Gy. However, the decrease in QoL scores, in general, was more pronounced in the high-dose than in the low-dose arm and in the physical health than in the mental health domain. In both randomization arms, statistically significant decrease in QoL scores over time were seen in six scales, but the deterioration over time was
References (15)
- et al.
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study
Urology
(2003) - et al.
Turning the tide: Benefit finding after cancer surgery
Soc Sci Med
(2004) - et al.
Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study
Int J Radiat Oncol Biol Phys
(2007) - et al.
Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer. Preliminary results on late toxicity and quality of life
Int J Radiat Oncol Biol Phys
(2001) - et al.
Sexual function after three-dimensional conformal radiotherapy for prostate cancer: Results from a dose escalation trial
Int J Radiat Oncol Biol Phys
(2007)
Cited by (0)
Supported by the Dutch Cancer Society (Grants NKI 98-1830 and CKTO 96-10).
Conflict of interest: none.